NEW YORK--(BUSINESS WIRE)--Rosen Law Firm announces that, following discussions with management and having gained a better understanding of the facts surrounding Heat Biologic’s (NASDAQ:HTBX) recent bladder cancer trial for Vesigenurtacel-L (HS-410), including the positive immunological data generated from this trial, it is closing its investigation of HTBX. Rosen attorney Phil Kim stated “We have concluded that there is no suggestion that management misrepresented the results of the clinical trial, and there is no basis for any securities claims.”
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.